Edwards Lifesciences Q1 EPS Beat, Guidance Raised

Edwards Lifesciences reported Q1 adjusted EPS of $0.78, beating consensus $0.73, and revenue $1.65 bn, up 16.7% YoY.
Company lifted FY2026 constant‑currency sales growth outlook to 9‑11% and full‑year EPS target to $2.95‑$3.05, above analyst expectations.
Shares rose about 4% after the release; Q2 revenue guidance $1.66‑$1.74 bn, EPS $0.70‑$0.76, slightly missing consensus.
TAVR sales climbed 14.4% to $1.20 bn, prompting full‑year TAVR growth guidance increase to 7‑9% from 6‑8%.